Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

269.05 USD -1.26 (-0.47%)
Official Closing Price Updated: 5:05 PM EDT, Apr 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
From GlobeNewswire News Releases
New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
From GlobeNewswire News Releases
Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
From GlobeNewswire News Releases
Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
From GlobeNewswire News Releases
The Road to a 100% Electric Vehicle Fleet
Tags Green Infrastructure NASDAQ:BIIB Electric Vehicles
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor... 
From Business Wire News Releases
Biogen Announces Two New Nominees for Election to Board of Directors
From GlobeNewswire News Releases
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
From GlobeNewswire News Releases
The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
From GlobeNewswire News Releases
Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
From GlobeNewswire News Releases
Biogen Inc. (NASDAQ:BIIB) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/02/2021 -- Certain directors of Biogen Inc are under investigation concerning potential breaches of fiduciary duties. 
From SBWire - Latest Press Releases
Telemedicine and Wellness Apps Have Showcased Tremendous Growth Due To Pandemic
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Telemedicine and Wellness Apps Have Showcased Tremendous Growth Due To Pandemic
- Financialnewsmedia.com News Commentary 
From PR Newswire
The Partnership, Inc. Launches New North Carolina Mid-Career Leadership Accelerator Program
Tags NASDAQ:BIIB Skills Development Economic Growth
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
From GlobeNewswire News Releases
Life Sciences Cares & Biogen Foundation Help Launch Food for Free's Just Eats Program
Tags Biogen Foundation Hunger Relief Philanthropy & Cause Initiatives
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Announces the Expiration Date Results of Its Cash Tender Offer
From GlobeNewswire News Releases
Biogen Announces the Expiration Date Results of Its Private Exchange Offer
From GlobeNewswire News Releases
Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups
From GlobeNewswire News Releases
Biogen Announces the Pricing Terms of its Cash Tender Offer
From GlobeNewswire News Releases
Biogen Announces the Pricing Terms of Its Private Exchange Offer
From GlobeNewswire News Releases
Biogen Offers Arcadia's Home Renewable Energy Program To Employees
Tags NASDAQ:BIIB Sustainability Energy
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
From GlobeNewswire News Releases
Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors
From GlobeNewswire News Releases
Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
From GlobeNewswire News Releases
Thinking about trading options or stock in Pfizer, Bed Bath & Beyond, American Airlines, Biogen, or iRobot?
InvestorsObserver issues critical PriceWatch Alerts for PFE, BBBY, AAL, BIIB, and IRBT. 
From PR Newswire
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
From GlobeNewswire News Releases
NASDAQ:BIIB Shareholder Notice: Deadline on January 12, 2021 in Lawsuit Against Biogen Inc.
San Diego, CA -- (SBWIRE) -- 01/12/2021 -- The Shareholders Foundation announced that a deadline is coming up on January 12, 2021 in the lawsuit filed for certain investors of Biogen Inc.... 
From SBWire - Latest Press Releases
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of... 
From PR Newswire
BIIB FILING DEADLINE TOMORROW: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.